SCHEDULE: Royalty Pharma: Stakeholder Exits Filing

Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have filed an exit report for their beneficial ownership of Royalty Pharma plc Class A Ordinary Shares, indicating a reduction in their stake to below 5%.

Summary

• This filing is an amendment to a Schedule 13D, serving as an exit filing for Butterfield Fiduciary Administrators Trust Company Limited (formerly R&H Trust Co. (Guernsey) Limited) and Mr. Achille G. Severgnini, collectively referred to as the Reporting Persons.
• The Reporting Persons have reduced their beneficial ownership of Royalty Pharma plc's Class A Ordinary Shares to below 5% as of June 12, 2026.
• Butterfield Fiduciary Administrators Trust Company Limited is the trustee for the MGG Trust and GG Trust, which are the economic owners of shares held by MGG Strategic and GG Strategic, respectively.
• Mr. Achille G. Severgnini is the protector of these trusts and has the power to remove and replace the trustee.
• The filing details sales of Class A Ordinary Shares by GG Strategic and MGG Strategic during the 60-day period ending June 12, 2026, with transactions occurring in the open market.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the exit of significant stakeholders, which can sometimes precede or coincide with negative price movements, although the sales were orderly.

Positives

• The Reporting Persons have successfully reduced their stake in Royalty Pharma plc, potentially indicating a strategic decision to divest or rebalance their portfolio.
• The sales were conducted in the open market, suggesting a controlled and orderly exit strategy.
• The filing is presented as a final amendment, signaling a clear conclusion to the Reporting Persons' significant ownership position.

Negatives

• The sale of a significant number of shares by entities associated with the Reporting Persons could be interpreted as a lack of confidence in the company's immediate future prospects by these stakeholders.
• The aggregate number of shares sold is substantial, potentially impacting market sentiment if not absorbed smoothly.

Risks

• The sale of shares by significant stakeholders could lead to increased share price volatility in the short term.
• The potential for further sales by these entities, although this is an exit filing, cannot be entirely ruled out without explicit confirmation.

Future Outlook

This filing represents an exit for the Reporting Persons, indicating they no longer hold a significant beneficial ownership stake (above 5%) in Royalty Pharma plc. No forward-looking statements regarding the company's performance are made by the Reporting Persons in this document.

Management Comments

• Each member of the board of directors for MGG SICAF and GG 1978 SICAF disclaims beneficial ownership over the shares managed by their respective SICAFs.
• Each of M. Germano Giuliani and Giammaria Giuliani disclaim beneficial ownership over the shares beneficially owned by MGG Strategic and GG Strategic.
• Each of Butterfield Fiduciary Administrators Trust Company Limited and Mr. Severgnini disclaim beneficial ownership over the shares beneficially owned by the Trusts.
• Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Persons are the beneficial owner of the Class A Shares referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose and each of the Reporting Persons expressly disclaims beneficial ownership of such Class A Shares and any assertion or presumption that it or he and the other persons on whose behalf this statement is filed constitute a 'group.'

Industry Context

StockSavvy.ai notes that Schedule 13D filings, particularly exit filings like this one, are crucial for understanding shifts in significant ownership stakes. Such changes can signal evolving investor sentiment or strategic realignments within the pharmaceutical and biotechnology investment landscape.

Stakeholder Impact

• Shareholders: The sale of a significant block of shares could lead to short-term price pressure. However, the orderly nature of the sales and the exit filing suggest a planned divestment rather than a distressed sale.
• Company Management: The reduction in ownership by these entities may alter the dynamics of shareholder engagement, though the specific impact depends on the remaining shareholder base and the company's governance structure.

Next Steps

• The Reporting Persons have completed their exit from significant beneficial ownership of Royalty Pharma plc Class A Ordinary Shares.
• The filing serves as a final amendment to the Schedule 13D.

Key Dates

Recommendation

This filing primarily concerns changes in beneficial ownership and serves as an exit report for specific entities. It does not contain operational or financial performance data for Royalty Pharma plc itself. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor the company's performance through its regular financial reports rather than reacting solely to this ownership change.

Keywords

Royalty Pharma, Schedule 13D, Exit Filing, Butterfield Fiduciary Administrators Trust Company Limited, Achille G. Severgnini, Class A Ordinary Shares, Beneficial Ownership, Stock Sales, SEC Filing